呼吸器感染症におけるT-2588の使用経験

小田切 繁樹; 松村 正典; 鈴木 周雄; 室橋 光宇; 渡部 紳一郎; 鈴木 尚子; 吉池 保博; 木内 充世

doi:10.11250/chemotherapy1953.34.Supplement2_392

CLINICAL STUDIES OF T-2588 IN RESPIRATORY TRACT INFECTIONS

SHIGEKI ODAGIRI, MASANORI MATSUMURA, KANEO SUZUKI, KOU MUROHASHI, SHINICHIRO WATABE, HISAKO SUZUKI, YASUHIRO YOSHIIKE, MITSUYO KIUCHI

Author information

SHIGEKI ODAGIRI
Department of Respiratory Disease, Kanagawa Prefectural Nagahama Hospital
MASANORI MATSUMURA
Department of Respiratory Disease, Kanagawa Prefectural Nagahama Hospital
KANEO SUZUKI
Department of Respiratory Disease, Kanagawa Prefectural Nagahama Hospital
KOU MUROHASHI
Department of Respiratory Disease, Kanagawa Prefectural Nagahama Hospital
SHINICHIRO WATABE
Department of Respiratory Disease, Kanagawa Prefectural Nagahama Hospital
HISAKO SUZUKI
Department of Respiratory Disease, Kanagawa Prefectural Nagahama Hospital
YASUHIRO YOSHIIKE
Department of Respiratory Disease, Kanagawa Prefectural Nagahama Hospital
MITSUYO KIUCHI
Department of Respiratory Disease, Kanagawa Prefectural Nagahama Hospital

JOURNAL FREE ACCESS

1986 Volume 34 Issue Supplement2 Pages 392-403

DOI https://doi.org/10.11250/chemotherapy1953.34.Supplement2_392

Details

Abstract

Nineteen patients with respiratory tract infections were treated with T-2588, a new cephem antimicrobial agent. The drug was administered orally at daily doses of 300-600mg divided into 3 for 3-28 days. The clinical effects were excellent in 4, good in 10, fair in 4, unknown in 1.
The efficacy rate was 77.8%. No side effects nor abnormal laboratory findings due to the drug were observed.

Corresponding author

Register with J-STAGE for free!